These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15388474)

  • 1. Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.
    Hoellman DB; Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4037-9. PubMed ID: 15388474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
    Huang V; Brown WJ; Rybak MJ
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
    Lin G; Credito K; Ednie LM; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):770-2. PubMed ID: 15673763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
    Credito K; Lin G; Ednie LM; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4033-6. PubMed ID: 15388473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
    Bogdanovich T; Ednie LM; Shapiro S; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4210-9. PubMed ID: 16189100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
    Lin G; Appelbaum PC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):233-5. PubMed ID: 17997257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175).
    Miller K; Storey C; Stubbings WJ; Hoyle AM; Hobbs JK; Chopra I
    J Antimicrob Chemother; 2005 Apr; 55(4):579-82. PubMed ID: 15722396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
    Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
    Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China.
    Wang H; Liu Y; Sun H; Xu Y; Xie X; Chen M
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):226-9. PubMed ID: 18653301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antibacterial activity of TOC-50, a new parenteral cephalosporin against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Nomura S; Hanaki H; Unemi N
    Chemotherapy; 1996; 42(4):253-8. PubMed ID: 8804792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.